VolitionRx Limited is a biotech company focused on developing blood tests for detecting a range of cancers and other diseases. Utilizing its innovative Nu.Q platform, VolitionRx aims to provide non-invasive, cost-effective diagnostic solutions that facilitate early detection and improve patient outcomes. The company's core technology revolves around identifying unique nucleosomes circulating in the blood, indicative of cancer and other conditions. By targeting broad applications in oncology, VolitionRx positions itself at the forefront of health diagnostics, impacting sectors such as healthcare, pharmaceuticals, and medical research. Headquartered in Austin, Texas, with a significant presence in Belgium, VolitionRx collaborates with leading institutions to validate its diagnostic tools. As precision medicine and early diagnosis continue to receive heightened focus in the medical community, VolitionRx's cutting-edge solutions hold a vital role in advancing healthcare and potentially saving lives through earlier intervention.